With $44M fundraise, could Fractyl make bariatric surgery the penicillin of our generation?
Fractyl Laboratories has raised a $44 million Series D financing round to build upon a chance discovery that bariatric surgery can resolve Type 2 diabetes in a subset of patients — independent of any weight loss.